FDA Joint Panel Recommends Relaxing Avandia Restrictions

A conflicted joint FDA advisory committee voted Thursday to ease restrictions on sales of GlaxoSmithKline’s (GSK) diabetes drug Avandia but stopped short of recommending removal of the drug’s strict risk evaluation and mitigation strategy (REMS) program.
Drug Industry Daily